Abstract
The need for dosimetric calculations has arisen to enhance the therapeutic efficacy of Yttrium-90 (Y-90) microsphere therapy, determine tumor absorbed dose threshold values, and accurately identify lung tolerance dose thresholds and liver toxicity thresholds. In microsphere therapies, there are three different dosimetry approaches: standard dosimetry, multicompartment dosimetry, and voxel-based dosimetry. Dosimetric procedures are generally performed using Technetium-99m macroaggregated albumin. However, dosimetry based on scintigraphic images obtained from positron emission tomography/computed tomography (CT) or single photon emission computerized tomography/CT after Y-90 administration is also feasible.
Keywords: Y-90 dosimetry, Y-90 microsphere dosimetry, Y-90 radioembolization treatment dosimetry
References
Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17-29.
Lam M, Garin E, Maccauro M, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2020;49:3340-3352.
Chiesa C, Mira M, Bhoori S, et al. Radioembolization of hepatocarcinoma with 90 Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47:-3032.
d’Abadie P, Hesse M, Jamar F, Lhommel R, Walrand S. 90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol. 2018;63:245010.
Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after 90y-radioembolization with glass microspheres using 90Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol. 2018;102:451-461.
Dewaraja YK, Devasia T, Kaza RK, et al. Prediction of tumor control in 90Y radioembolization by logit models with PET/CT-based dose metrics. J Nucl Med 2020;61:104-111.
Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2021;38:4824-4845.
Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F. Therapy, Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011,38:1393-1406.
Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682-1699.
Chiesa C, Sjogreen-Gleisner K, Walrand S, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99m Tc-MAA pre-and 90 Y peri-therapy dosimetry in liver radioembolization with 90 Y microspheres. EJNMMI Phys. 2021;8:1-44.
Hemmingsson J, Högberg J, Mölne J, et al. Autoradiography and biopsy measurements of a resected hepatocellular carcinoma treated with 90 yttrium radioembolization demonstrate large absorbed dose heterogeneities. Adv Radiat Oncol. 2018;3:439-446.
Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 20024;60:439-446.
Lambert B, Sturm E, Mertens J, et al. Intra-arterial treatment with 90 Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging. 2011;38:2117-2124.
Wright C, Binzel K, Zhang J, Wuthrick E, Tung CH, Knopp M. Clinical impact of quantitative post-radioembolization 90Y PET/CT using next-generation digital photon counting PET detectors. Int J Comput Assist Radiol Surg. 2016;11.
Jiang M, Fischman A, Nowakowski FS. Segmental perfusion differences on paired Tc-99m macroaggregated albumin (MAA) hepatic perfusion imaging and Yttrium-90 (Y-90) Bremsstrahlung imaging studies in SIR-sphere radioembolization: associations with angiography. J Nucl Med Radiat Ther. 2012;03:122.
Wondergem M, Smits M L, Elscho, M, et al. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54:1294-1301.
Kao YH, Steinberg JD, Tay YS, et al. Post-radioembolization yttrium-90 PET/CT-part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res. 2013;3:1-12.
Gnesin S, Canetti L, Adib S, et al. Partition model-based 99mTc-MAA SPECT/CT predictive dosimetry compared with 90Y TOF PET/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57:1672-1678.
Haste P, Tann M, Persohn S, et al. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography/CT. J Vasc Interv Radiol. 2017;28:722-730.
Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for 90Y radioembolization with glass microspheres: evaluating the fidelity of 99mTc-MAA and partition model predictions. Med Phys. 2020;47:5333-5342.
Chiesa C. The individualized dosimetry in the radioembolization of hepatocarcinoma with 90Y-microspheres. Physica Medica. 2016;32:169-170.
Cremonesi M, Chiesa C, Strigari L, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;4:210.
Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976-1988.
Botta F, Ferrari M, Chiesa C, et al. Impact of missing attenuation and scatter corrections on 99mTc‐MAA SPECT 3D dosimetry for liver radioembolization using the patient relative calibration methodology: A retrospective investigation on clinical images. Med Phys. 2018;45:1684-1698.
Elschot M, Vermolen BJ, Lam GEH, de Keizer B, van den Bosch MAAJ, de Jong HVAM. Quantitative comparison of PET and bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One. 2013;8:2013.
Lhommel R, Goffette P, Van den Eynde M, et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging. 2009;36:1696-1696.
Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919-924.
Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:919-924.
Gill H, Hiller J. Systematic review of lung shunt fraction quantification comparing SPECT/CT and planar scintigraphy for yttrium 90 radioembolization planning. Clinical and Translational Imaging. 2021;9:2021.
Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8:233-240.
Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48:1570-1584.
Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32:5-265.
